Application of PBPK Modeling and Simulation for Regulatory Decision Making and Its Impact on US Prescribing Information: An Update on the 2018-2019 Submissions to the US FDA's Office of Clinical Pharmacology

被引：129

作者：

Zhang, Xinyuan ^{[1
]}

Yang, Yuching ^{[1
]}

Grimstein, Manuela ^{[1
]}

Fan, Jianghong ^{[1
]}

Grillo, Joseph A. ^{[1
]}

Huang, Shiew-Mei ^{[1
]}

Zhu, Hao ^{[1
]}

Wang, Yaning ^{[1
]}

机构：

[1] US FDA, Off Clin Pharmacol, Off Translat Sci, Ctr Drug Evaluat & Res, Silver Spring, MD USA

来源：

JOURNAL OF CLINICAL PHARMACOLOGY | 2020年 / 60卷

关键词：

clinical pharmacology (CPH); drug‐ drug interactions; MIDD (model‐ informed drug development); modeling and simulation; PBPK; pharmacokinetics and drug metabolism; DRUG-DRUG INTERACTIONS; PREDICTION;

D O I：

10.1002/jcph.1767

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Since 2016, results from physiologically based pharmacokinetic (PBPK) analyses have been routinely found in the clinical pharmacology section of regulatory applications submitted to the US Food and Drug Administration (FDA). In 2018, the Food and Drug Administration's Office of Clinical Pharmacology published a commentary summarizing the application of PBPK modeling in the submissions it received between 2008 and 2017 and its impact on prescribing information. In this commentary, we provide an update on the application of PBPK modeling in submissions received between 2018 and 2019 and highlight a few notable examples.

引用

页码：S160 / S178

页数：19

共 19 条

[1] Pharmacokinetic Drug-Drug Interaction of Apalutamide, Part 1: Clinical Studies in Healthy Men and Patients with Castration-Resistant Prostate Cancer
Duran, Ignacio
Carles, Joan
Bulat, Iurie
Hellemans, Peter
Mitselos, Anna
Ward, Peter
Jiao, James
Armas, Danielle
Chien, Caly
[J]. CLINICAL PHARMACOKINETICS, 2020, 59 (09) : 1135 - 1148
[2] Physiologically Based Pharmacokinetic Modeling in Regulatory Science: An Update From the US Food and Drug Administration's Office of Clinical Pharmacology
Grimstein, Manuela
Yang, Yuching
Zhang, Xinyuan
Grillo, Joseph
Huang, Shiew-Mei
Zineh, Issam
Wang, Yaning
[J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 108 (01) : 21 - 25
[3] In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics
Jin, Yi
Borell, Hubert
Gardin, Anne
Ufer, Mike
Huth, Felix
Camenisch, Gian
[J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 74 (04) : 455 - 464
[4] Prediction of Transporter-Mediated Drug-Drug Interactions for Baricitinib
Posada, Maria M.
Cannady, Ellen A.
Payne, Christopher D.
Zhang, Xin
Bacon, James A.
Pak, Y. Anne
Higgins, J. William
Shahri, Nazila
Hall, Stephen D.
Hillgren, Kathleen M.
[J]. CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2017, 10 (06): : 509 - 519
[5] Prediction of Renal Transporter Mediated Drug-Drug Interactions for Pemetrexed Using Physiologically Based Pharmacokinetic Modeling
Posada, Maria M.
Bacon, James A.
Schneck, Karen B.
Tirona, Rommel G.
Kim, Richard B.
Higgins, J. William
Pak, Y. Anne
Hall, Stephen D.
Hillgren, Kathleen M.
[J]. DRUG METABOLISM AND DISPOSITION, 2015, 43 (03) : 325 - 334
[6] Physiologically-Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug-Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations
Taskar, Kunal S.
Pilla Reddy, Venkatesh
Burt, Howard
Posada, Maria M.
Varma, Manthena
Zheng, Ming
Ullah, Mohammed
Emami Riedmaier, Arian
Umehara, Ken-ichi
Snoeys, Jan
Nakakariya, Masanori
Chu, Xiaoyan
Beneton, Maud
Chen, Yuan
Huth, Felix
Narayanan, Rangaraj
Mukherjee, Dwaipayan
Dixit, Vaishali
Sugiyama, Yuichi
Neuhoff, Sibylle
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 (05) : 1082 - 1115
[7] Meta-Analysis of Hepatic Cytochrome P450 Ontogeny to Underwrite the Prediction of Pediatric Pharmacokinetics Using Physiologically Based Pharmacokinetic Modeling
Upreti, Vijay V.
Wahlstrom, Jan L.
[J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (03) : 266 - 283
[8] US Food and Drug Administration, 2016, Guidance for industry: clinical pharmacology data to support a demonstration of biosimilarity to a reference product
[9] US Food and Drug Administration, 2018, NDA211192 US FDA
[10] US Food and Drug Administration, 2018, 210496 NDA US FDA

← 1 2 →